Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

The role of delamanid in the treatment of drug-resistant tuberculosis

Authors Lewis J, Sloan D

Received 7 February 2015

Accepted for publication 31 March 2015

Published 13 May 2015 Volume 2015:11 Pages 779—791


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Professor Garry Walsh

Joseph M Lewis,1 Derek J Sloan2,3

1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK

Abstract: Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

Keywords: delamanid, OPC-67683, tuberculosis, drug resistance, MDR-TB

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]